Tags

Type your tag names separated by a space and hit enter

3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Eur J Med Chem. 2009 Jul; 44(7):2868-76.EJ

Abstract

Histone deacetylases (HDACs) enzyme is a promising target for the development of anticancer drugs. The enzyme-bound conformation of Trichostatin A (TSA) (PDB ID:1C3R) as an inhibitor of HDACs was used to manually construct a pharmacophore model. This model was then successfully used to identify the bioactive conformation and align flexible and structurally diverse molecules. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on hydroxamate-based HDACs inhibitors based on phamacophore alignment. The best predictions were obtained with CoMFA standard model (q(2) = 0.726, r(2) = 0.998) and CoMSIA model combined with steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor fields (q(2) = 0.610, r(2) = 0.995). Both of the models were validated by an external test set, which gave a satisfactory predictive r(2) value of 0.800 and 0.732, respectively. Graphical interpretation of the results revealed important structural features of the inhibitors related to the active site of HDACs. The results may be exploited for further design and virtual screening for some novel HDACs inhibitors.

Authors+Show Affiliations

Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19136179

Citation

Chen, Yadong, et al. "3D-QSAR Studies of HDACs Inhibitors Using Pharmacophore-based Alignment." European Journal of Medicinal Chemistry, vol. 44, no. 7, 2009, pp. 2868-76.
Chen Y, Li H, Tang W, et al. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009;44(7):2868-76.
Chen, Y., Li, H., Tang, W., Zhu, C., Jiang, Y., Zou, J., Yu, Q., & You, Q. (2009). 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. European Journal of Medicinal Chemistry, 44(7), 2868-76. https://doi.org/10.1016/j.ejmech.2008.12.008
Chen Y, et al. 3D-QSAR Studies of HDACs Inhibitors Using Pharmacophore-based Alignment. Eur J Med Chem. 2009;44(7):2868-76. PubMed PMID: 19136179.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. AU - Chen,Yadong, AU - Li,Huifang, AU - Tang,Wanquan, AU - Zhu,Chengchao, AU - Jiang,Yongjun, AU - Zou,Jianwei, AU - Yu,Qingsen, AU - You,Qidong, Y1 - 2008/12/16/ PY - 2008/09/03/received PY - 2008/12/01/revised PY - 2008/12/05/accepted PY - 2009/1/13/entrez PY - 2009/1/13/pubmed PY - 2009/7/25/medline SP - 2868 EP - 76 JF - European journal of medicinal chemistry JO - Eur J Med Chem VL - 44 IS - 7 N2 - Histone deacetylases (HDACs) enzyme is a promising target for the development of anticancer drugs. The enzyme-bound conformation of Trichostatin A (TSA) (PDB ID:1C3R) as an inhibitor of HDACs was used to manually construct a pharmacophore model. This model was then successfully used to identify the bioactive conformation and align flexible and structurally diverse molecules. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on hydroxamate-based HDACs inhibitors based on phamacophore alignment. The best predictions were obtained with CoMFA standard model (q(2) = 0.726, r(2) = 0.998) and CoMSIA model combined with steric, electrostatic, hydrophobic, hydrogen bond donor and acceptor fields (q(2) = 0.610, r(2) = 0.995). Both of the models were validated by an external test set, which gave a satisfactory predictive r(2) value of 0.800 and 0.732, respectively. Graphical interpretation of the results revealed important structural features of the inhibitors related to the active site of HDACs. The results may be exploited for further design and virtual screening for some novel HDACs inhibitors. SN - 1768-3254 UR - https://www.unboundmedicine.com/medline/citation/19136179/3D_QSAR_studies_of_HDACs_inhibitors_using_pharmacophore_based_alignment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0223-5234(08)00596-5 DB - PRIME DP - Unbound Medicine ER -